Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers-Reference-Cited by-同舟云学术

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

Published:2017-11-08 Issue:415 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Nilsson Monique B.¹^ORCID,Sun Huiying¹^ORCID,Diao Lixia²^ORCID,Tong Pan²,Liu Diane³^ORCID,Li Lerong²,Fan Youhong¹,Poteete Alissa¹^ORCID,Lim Seung-Oe⁴^ORCID,Howells Kathryn⁵,Haddad Vincent⁵^ORCID,Gomez Daniel⁶,Tran Hai¹,Pena Guillermo Armaiz⁷,Sequist Lecia V.⁸^ORCID,Yang James C.⁹^ORCID,Wang Jing²,Kim Edward S.¹⁰^ORCID,Herbst Roy S.¹¹,Lee J. Jack³^ORCID,Hong Waun Ki¹,Wistuba Ignacio¹¹²^ORCID,Hung Mien-Chie⁴^ORCID,Sood Anil K.⁷,Heymach John V.¹^ORCID

Affiliation:

1. Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

2. Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

3. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

4. Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

5. AstraZeneca, Melbourn, SG8 6EE, UK.

6. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

7. Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

8. Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.

9. Graduate Institute of Oncology, National Taiwan University and National Taiwan University Hospital, Taipei City 100, Taiwan.

10. Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute Carolinas HealthCare System, Charlotte, NC 28204, USA.

11. Section of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, Yale, New Haven, CT 06510, USA.

12. Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Abstract

Chronic stress hormones promote EGFR inhibitor resistance in EGFR mutant non–small cell lung cancer.

Funder

National Cancer Institute

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference65 articles.

1. Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer: Fig. 1.

2. EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

3. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

4. AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

5. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression of the non-coding RNA nc886 facilitates the development of tyrosine kinase inhibitor resistance in EGFR-mutated non-small-cell lung cancer cells;Biochemical and Biophysical Research Communications;2024-10

2. Recent Computational Approaches in Understanding the Links between Molecular Stress and Cancer Metastasis;BioMedInformatics;2024-07-31

3. Nerve-tumor crosstalk in tumor microenvironment: From tumor initiation and progression to clinical implications;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-07

4. Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer;Nature Medicine;2024-05-13

5. Adrenergic microenvironment driven by cancer‐associated Schwann cells contributes to chemoresistance in patients with lung cancer;Cancer Science;2024-04-27